Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 19/20 | 0.39 |
| ▸ | CTSK | P43235 | 7/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4109181 | 0.88 | ALDH1A1 (0.36) | CTSSMAOAMAOB | |
| SCHEMBL4093553 | 0.87 | MAOA (0.43) | CTSSMAOAMAOB | |
| SCHEMBL4104374 | 0.82 | ALDH1A1 (0.35) | CTSSMAOAMAOB | |
| SCHEMBL4104142 | 0.82 | MAOA (0.42) | MAOAMAOB | |
| SCHEMBL5438324 | 0.81 | ALDH1A2 (0.38) | CTSSCTSKMAOB | |
| SCHEMBL5428589 | 0.80 | ALDH1A2 (0.37) | CTSSMAOAMAOB | |
| SCHEMBL4099332 | 0.78 | CNR1 (0.41) | CTSSCTSKMAOAMAOB | |
| SCHEMBL2235680 | 0.77 | CTSS (0.36) | CTSSCTSK | |
| SCHEMBL4426575 | 0.77 | CTSS (0.36) | CTSSCTSK | |
| SCHEMBL1997999 | 0.76 | TRPV1 (0.37) | CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233947-A1 | 2,3-Substituted fused bicyclic pyrimidin-4(3H)-ones which modulating the function of the vanilloid -1 receptor (VR1) | MERCK SHARP & DOHME LTD. (GB) | 2009-09-17 | — | — | US | claimed |
| EP-1888586-A2 | 2,3-SUBSTITUTED FUSED BICYCLIC PYRIMIDIN-4(3H)-ONES WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) | MERCK SHARP & DOHME LTD. (GB) | 2008-02-20 | — | — | EP | claimed |
| WO-2006120481-A2 | 2,3-SUBSTITUTED FUSED BICYCLIC PYRIMIDIN-4(3H)-ONES WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) | MERCK SHARP & DOHME LIMITED (GB) | 2006-11-16 | — | — | WO | claimed |
| US-20090233947-A1 | 2,3-Substituted fused bicyclic pyrimidin-4(3H)-ones which modulating the function of the vanilloid -1 receptor (VR1) | MERCK SHARP & DOHME LTD. (GB) | 2009-09-17 | — | — | US | disclosed |
| EP-1888586-A2 | 2,3-SUBSTITUTED FUSED BICYCLIC PYRIMIDIN-4(3H)-ONES WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) | MERCK SHARP & DOHME LTD. (GB) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006120481-A2 | 2,3-SUBSTITUTED FUSED BICYCLIC PYRIMIDIN-4(3H)-ONES WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) | MERCK SHARP & DOHME LIMITED (GB) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233947-A1 | 2,3-Substituted fused bicyclic pyrimidin-4(3H)-ones which modulating the function of the vanilloid -1 receptor (VR1) | TRPV1, TRPV2, TRPV3 | CTSS 4006/4885CTSK 3649/4885MAOA 3635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.